Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-04-11, Stock:NVS, The news for the past five days is as follows:
2019-04-04: NEWS1: Novartis, Amgen in dispute over migraine drug partnership.NEWS2: Top Analyst Reports for Amazon, 3M & Novartis.NEWS3: Top Analyst Reports for Amazon, 3M & Novartis.NEWS4: 3 Ways to Buy Into the Marijuana Boom Without the Risk.NEWS5: 3 Ways to Buy Into the Marijuana Boom Without the Risk.NEWS6: 1 Biotech That Biogen Should Buy ... but Probably Won&apos;t.NEWS7: Top Analyst Reports for Amazon, 3M & Novartis.NEWS8: Achillion Meets Enrollment Target in Kidney Disease Studies.NEWS9: Achillion Meets Enrollment Target in Kidney Disease Studies.NEWS10: Novartis Resubmits BLA to FDA for Biosimilar of Neulasta.NEWS11: Novartis Resubmits BLA to FDA for Biosimilar of Neulasta.NEWS12: Novartis sues Amgen over migraine treatment Aimovig.NEWS13: Achillion Meets Enrollment Target in Kidney Disease Studies.NEWS14: Novartis Resubmits BLA to FDA for Biosimilar of Neulasta.NEWS15: Novartis CEO&apos;s $50 Billion of Deals Was Just the First Act.
2019-04-05: NEWS1: Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig.NEWS2: Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig.NEWS3: Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU.NEWS4: Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU.NEWS5: The Zacks Analyst Blog Highlights: Amazon, 3M, Novartis, Schlumberger and ICICI.NEWS6: The Zacks Analyst Blog Highlights: Amazon, 3M, Novartis, Schlumberger and ICICI.NEWS7: Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU.NEWS8: Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig.NEWS9: Novartis Lawsuit Accuses Amgen Of Trying To Welsh On Migraine Deal.NEWS10: The Zacks Analyst Blog Highlights: Amazon, 3M, Novartis, Schlumberger and ICICI.NEWS11: The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership.
2019-04-08: NEWS1: Eye-Care Leader Alcon Is About to Hit the Stock Market.NEWS2: Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym.NEWS3: Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym.NEWS4: The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca.NEWS5: The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca.NEWS6: Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym.NEWS7: The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca.NEWS8: Lawsuit over migraine deal could be good for Amgen, analysts say.NEWS9: Why Amgen's Giving Novartis a Headache.NEWS10: Why Amgen's Giving Novartis a Headache.
2019-04-09: NEWS1: What Happened in the Stock Market Today.NEWS2: What Happened in the Stock Market Today.NEWS3: What Happened in the Stock Market Today.NEWS4: Health Care Sector Update for 04/09/2019: CERN,PHAS,CMRX,NVS,VXRT.NEWS5: Health Care Sector Update for 04/09/2019: CERN,PHAS,CMRX,NVS,VXRT.NEWS6: Novartis News: NVS Stock Sinks Following Alcon Spin-Off.NEWS7: Novartis News: NVS Stock Sinks Following Alcon Spin-Off.NEWS8: Here's Why Novartis Is Sliding Today.NEWS9: Here's Why Novartis Is Sliding Today.NEWS10: Health Care Sector Update for 04/09/2019: PHAS,CMRX,NVS,VXRT.NEWS11: Health Care Sector Update for 04/09/2019: PHAS,CMRX,NVS,VXRT.NEWS12: Here&apos;s Why Novartis Is Sliding Today.NEWS13: NVS Crosses Below Key Moving Average Level.NEWS14: NVS Crosses Below Key Moving Average Level.NEWS15: Novartis is Now Oversold (NVS).NEWS16: Novartis is Now Oversold (NVS).NEWS17: Alcon Begins Trading After Spinoff From Novartis.NEWS18: Novartis News: NVS Stock Sinks Following Alcon Spin-Off.NEWS19: European ADRs Move Higher in Tuesday Trading.NEWS20: European ADRs Move Higher in Tuesday Trading.NEWS21: Alcon CEO on where the company is headed following spin-off from Novartis.NEWS22: Alcon Stock Is Trading Strongly in Its U.S. Debut After the Novartis Spinoff.NEWS23: Health Care Sector Update for 04/09/2019: VXRT, ZGNX, NVS, JNJ, PFE, ABT, MRK, AMGN.NEWS24: Health Care Sector Update for 04/09/2019: VXRT, ZGNX, NVS, JNJ, PFE, ABT, MRK, AMGN.NEWS25: Pre-Market Most Active for Apr 9, 2019 :  ZGNX, NVS, QQQ, X, PHAS, GE, AAPL, CHK, SQQQ, NOK, AMD, ACB.NEWS26: Pre-Market Most Active for Apr 9, 2019 :  ZGNX, NVS, QQQ, X, PHAS, GE, AAPL, CHK, SQQQ, NOK, AMD, ACB.NEWS27: The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing.NEWS28: Alcon tops $28 billion market cap in decade's biggest Swiss stock deal.NEWS29: Alcon tops $28 bln market cap in decade's biggest Swiss stock deal.NEWS30: Top 5 Things to Know in The Market on Tuesday.NEWS31: FirstFT: Today’s top stories.NEWS32: Novartis to limit M&A spend to 5% of market value.NEWS33: Alcon/Novartis: eye inflection.
2019-04-10: NEWS1: What Alcon’s Spinoff Can Teach Bausch Health.NEWS2: 5 Companies Paying High Dividend Yields.NEWS3: Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval.NEWS4: Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval.NEWS5: Alcon Can See Clearly Now.NEWS6: Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval.NEWS7: Analysts Predict 13% Upside For The Holdings of ADRD.NEWS8: Analysts Predict 13% Upside For The Holdings of ADRD.NEWS9: Second Time's The Charm For Amgen As FDA OKs Bone-Building Osteoporosis Drug.NEWS10: Q1 Cannabis Wholesale Report: Best-Selling Brands And Products, Pharma, CBD And Interstate Commerce.

Answer: Decrease